X

AggregoTV

Top Videos
ESMO Vision stories of Integrated Cancer Care: Verna Vanderpuye, Ghana

"I think ESMO is poised to do that and I think we have a bright future ahead of us," says ESMO member Verna Vanderpuye from Ghana.

10/23/2020
What is the Evidence that Fecal Microbiota Transplantation Can Cure GvHD?

Mette Hazenberg, Amsterdam UMC discusses evidence that fecal microbiota transplantation can cure GvHD.

12/14/2020

AggregoTV

`
ESMO Vision Stories of Sustainable Cancer Care: Andrea Sbrana

Is statistically significant the same as clinically significant? The ESMO-MCBS has been thought to try and answer this question even when talking about newer treatments, explains Andrea Sbrana.

12/17/2020
Leukemia, Lymphoma, Myeloma, and Immunotherapy with Dr. Philip Greenberg

Dr. Philip Greenberg discusses how immunotherapy works for blood cancers, promising immunotherapy clinical trials, as well as potential side effects.

12/11/2020
Pancreatic Cancer and Immunotherapy with Dr. Elizabeth M. Jaffee

Join Dr. Elizabeth Jaffee of the Bloomberg~Kimmel Institute for Cancer Immunotherapy for a Q&A discussion about immunotherapies in clinical trials for pancreatic cancer.

12/11/2020
Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz

Dr. Scott Kopetz discusses the latest breakthroughs and future promise of immunotherapy for colorectal cancer patients.

12/11/2020
What is the Evidence that Fecal Microbiota Transplantation Can Cure GvHD?

Mette Hazenberg, Amsterdam UMC discusses evidence that fecal microbiota transplantation can cure GvHD.

12/14/2020

AggregoTV - AML

High Dose Therapy and Autologous Stem Cell Transplantation
red blood cells

Discussion on high dose therapy and autologous stem cell transplantation.

New Approaches for AML Patients Who Are Not Candidates for Intensive Therapy

Dr Stéphane de Botton discusses novel treatment approached for patients with acute myeloid leukemia who are not candidates for intensive therapy.

06/27/2021
Understanding Risk in AML: How Molecular Testing Affects Treatment Options

How does molecular testing impact AML treatment options? Dr. Pinkal Desai discusses molecular testing and how results may help determine the best treatment path for patients.

11/19/2020
Treatment Cessation Using Venetoclax-Based Therapy for Older Patients With AML

Dr Andrew Wei discusses the combination of venetoclax with low-dose therapy as a new standard of care for older patients with AML who have not received prior treatment...

06/28/2021
Impact of Splicing Factor Mutations on AML Treatment

Dr Curtis Lachowiez discusses a recent paper investigating splicing factor mutations in patients with acute myeloid leukemia.

06/07/2021

AggregoTV - NSCLC

Checkpoint Inhibitors - Alone or With Chemotherapy in Lung Cancer?

Should patients with lung cancer with high PD-L1 expression be treated with checkpoint inhibitors alone or a combined checkpoint inhibitor and chemotherapy regimen? Dr Bruna Pellini highlights this as a major unanswered question in the field.

06/04/2021
IMpower010: Adjuvant Atezolizumab Improves DFS in Resected Stage II-IIIA NSCLC

Dr Heather Wakelee talks on the findings of IMpower010, a Phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC.

06/16/2021
Disease-Free Survival in IMpower010 Trial: Adjuvant Atezolizumab in NSCLC

Dr Sanjay Popat discusses results of the IMpower010 trial in patients with version 7 TNM, stage 1b resected non-small cell lung cancer.

07/02/2021
Bispecific Antibodies in Lung Cancer

Dr Benjamin Besse outlines the role of bispecific antibodies in treating lung cancer.

06/18/2021
Osimertinib + Ipilimumab in EGFR-Mutated NSCLC

Dr Sonam Puri discusses a trial which explores the combination of osimertinib, an EGFR TKI with ipilimumab, a monoclonal antibody drug in patients with EGFR mutant NSCLC as first line treatment.

07/08/2021
Candid Conversations in Lung Cancer: Discussing Biomarker Testing and Targeted Therapies

PeerView has partnered with the LUNGevity foundation to bring the patient perspective into education directed to oncology and pathology professionals, and highlight the importance of having open conversations...

06/12/2021

AggregoTV - DLBCL

Which New Therapeutics Are Generating Excitement at This Year’s ICML?

Dr Salles summarizes preclinical data on a histone deacetylase inhibitor investigated for T-cell lymphoma, as well as data on bispecific antibodies investigated for DLBCL.

06/28/2021
Sequencing Treatment Options in Primary Refractory DLBCL

 

Davies begins by outlining a specific patient case, caveats in the current treatment options for DLBCL, and the patterns of primary refractory DLBCL.

06/25/2021
First-in-Human Trial of ALLO-501A in R/R Large B-cell Lymphoma

Dr Michael Tees discusses the first-in-human data of ALLO-501A, an allogeneic CAR-T product under investigation in relapsed/refractory large B-cell lymphoma in the ALPHA2 study.

06/21/2021
Outcomes of CAR-T Therapy in Patients With Refractory B-Cell Lymphoma

Dr Bruce Levine reports on the outcomes for refractory B-cell Lymphoma patients with CAR T-cell therapy.

04/23/2021
R-CHOP Dose Intensity and Survival Outcomes in DLBCL

Chan Yoon Cheah, MBBS, discusses the results of a systematic review investigating the impact of R-CHOP dose intensity on survival outcomes in patients with DLBCL.

06/02/2021
IELSG30: Treating Primary Testicular DLBCL

Dr Annarita Conconi summarizes the results of the Phase II IELSG30 trial assessing R-CHOP, intravenous methotrexate, liposomal cytarabine, and scrotal irradiation in patients with primary DLBCL of the testis.

06/30/2021

AggregoTV - Sickle Cell Anemia

Pediatric Nursing - Epistaxis, Iron Deficiency Anemia, Sickle Cell Anemia and Hemophilia

Cathy Parkes, BSN, RN, discusses various bleeding disorders in children.

03/19/2021
Sickle Cell, COVID-19 and Vaccination

The Sickle Cell Society joins with clinicians and sickle cell patients from across the country to learn more about sickle cell and COVID-19 and to ask questions about the vaccines.

01/29/2021
NEET PG-Topic-Sickle Cell Anemia-Obstetrics & Gynecology

Sickle cell disease is the most common hemoglobinopathy encountered during pregnancy.

12/22/2020
COVID-19 Vaccine Spotlight on Sickle Cell Disease

Dr Titilope Fasipe, Co-Director of Texas Children’s Sickle Cell and Thalassemia Program, answers some of the most common questions about the COVID-19 vaccine and sickle cell disease.

02/08/2021
Loyola Medicine's Sickle Cell Anemia Program

Gail Kellberg, director of Loyola Medicine's sickle cell anemia program and Dr Kevin Smith discuss the program, specifically designed for the needs of the sickle cell patient population.

04/22/2021
Ep 7: Dr. Scott Discusses Sickle Cell and the Eye

Dr. Scott discusses the impacts of sickle cell disease regarding the eye, preventative measures, and her latest research.

04/01/2021
Spotlight
Colorectal Cancer and Immunotherapy with Dr. Scott Kopetz

Dr. Scott Kopetz discusses the latest breakthroughs and future promise of immunotherapy for colorectal cancer patients.

12/11/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834